Key result
The management of stable ischemic heart disease requires a comprehensive approach including risk-factor modification, optimal medical therapy for symptom relief and secondary prevention, and revascularization for refractory symptoms or high-risk features.
This review summarizes the current evidence for secondary prevention therapies, antianginal medications, and revascularization in the management of stable angina.
Medical therapy first-line for stable IHD; leaves open optimal strategies for refractory cases.
Angina is the clinical manifestation of myocardial ischemia and is most often due to coronary stenosis. The management of stable ischemic heart disease requires treatment aimed at both symptom relief and reduction of cardiovascular morbidity and mortality related to atherosclerosis. Risk-factor modification and medical therapy to prevent acute ischemic events and disease progression should be initiated after diagnosis. Patients with symptoms refractory to medical therapy, high-risk stress test results, or anatomic findings have an indication for coronary revascularization. This article addresses evidence that supports the use of secondary prevention therapies and the various antianginal medications that are available for the management of stable angina.
No takes yet. Share an insight, caveat, or question.
Crudu et al. (2013) conducted a review in Stable Angina Pectoris. Medical therapy and revascularization was evaluated. The management of stable ischemic heart disease requires a comprehensive approach including risk-factor modification, optimal medical therapy for symptom relief and secondary prevention, and revascularization for refractory symptoms or high-risk features.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: